01
Strategic financial roadmaps
Align corporate strategy, capital deployment, and financial planning across 3-, 5-, and 10-year planning horizons.
Executive Advisory
Long-range planning for biotech & pharma leaders
Long Range Advisory helps small and mid-sized biotechnology and pharmaceutical companies make smarter investment decisions through long-range planning, valuation modeling, and executive decision support. We build DCF, NPV, IRR, and scenario models that help leadership deploy capital with confidence.
Live valuation · base case
5 assetsAdjusted NPV
$4.08B
Risk-weighted by PoS
Unadjusted
$5.54B
Assumes technical success
Priced as risk
$1.46B
Implied share price
$9.34
Discount rate10.0%
LRA-045$1.88B
LRA-201$0.98B
LRA-114$0.45B
LRA-330$0.11B
LRA-078$0.66B
15+
Years of finance leadership
$20B+
Portfolio oversight
5+
Fortune 500 companies served
100+
Long-range planning models
Organizations served
AbbVie·Neurocrine Biosciences·Regeneron Pharmaceuticals·Fortune 500 life sciences·High-growth biotech
How we create value
Turning financial strategy into capital allocation
Long Range Advisory is a strategic finance consultancy that builds long-range plans, risk-adjusted valuations and capital allocation models for small and mid-sized biotechnology and pharmaceutical companies.
Long Range Advisory partners with biotechnology and pharmaceutical leadership teams to evaluate strategic investments through robust long-range planning and valuation modeling. We develop executive-ready financial models that quantify risk, compare investment alternatives, and support confident capital allocation decisions.
Whether evaluating pipeline investments, commercial expansion, licensing opportunities, or enterprise initiatives, we build practical financial models using DCF, NPV, IRR, scenario analysis, and sensitivity testing that support long-term shareholder value.
- An executive-ready model, not a black box
- A recommendation with the numbers behind it
- Scenarios your board can stress-test live
- A plan the finance team can maintain
Strategic finance challenges we help solve
02
Valuation & investment analysis
Evaluate pipeline assets and strategic investments using DCF, NPV, IRR, scenario modeling, and sensitivity analysis.
Advisory services
Data driven decisions
In today’s competitive business environment, smart decisions are powered by accurate data.
Live model
The valuation your board actually argues about
This is the sum-of-the-parts slide, live. Change the discount rate and the adjusted and unadjusted net present values re-solve instantly. Illustrative data only; no client information is used.
Adjusted NPV
$4.08B
Unadjusted
$5.54B
Implied share price
$9.34
Discount rate
10.0%
Discount rate10.0%
Swipe the table
| Code | Indication | Status | Launch | Peak sales | PoS | Adjusted NPV |
|---|---|---|---|---|---|---|
| LRA-045 | Major Depressive DisorderNeuropsychiatry | Filed | 2027 | $1,460M | 80% | $1.88B |
| LRA-201 | Post-Traumatic Stress DisorderNeuropsychiatry | Phase 3 | 2028 | $1,120M | 68% | $0.98B |
| LRA-114 | Generalized Anxiety DisorderNeuroscience | Phase 3 | 2029 | $730M | 58% | $0.45B |
| LRA-330 | Social Anxiety DisorderNeuroscience | Phase 2b | 2031 | $480M | 42% | $0.11B |
| LRA-078 | Chronic InsomniaSleep Medicine | Marketed | 2026 | $390M | 93% | $0.66B |
Valuation
Sum of the parts
Long-range plan
10-year P&L
Capital allocation
Where the money goes
Sensitivity
What moves the number
Illustrative pipeline. Adjusted NPV risk-weights every cash flow by probability of success; unadjusted assumes technical success. Figures are for demonstration only and are not investment advice.
Open the model labHow an engagement runs
Step 01
Scope the decision
One call to establish what is being decided, by whom, and by when.
Step 02
Fix the assumptions
Commercial forecast, development cost, timing and probability — agreed and documented.
Step 03
Build the model
An integrated long-range plan and valuation your team can open, read and maintain.
Step 04
Present to the board
The recommendation, the scenarios behind it, and the questions it must survive.
“Long Range Advisory gave us a financial model our executive team actually used to make investment decisions. The analysis brought clarity to our capital allocation process and significantly improved our long-range planning discussions.”
VP Finance
Mid-Size Biotechnology Company
Attributed as supplied · anonymous
Ask this site
Get the answer without the browse
Answers come straight from the pages on this site, with the source linked. Nothing is generated.
Answers
What people ask before the first call
What does Long Range Advisory do?
Long Range Advisory provides long-range planning, valuation modeling and executive decision support to small and mid-sized biotechnology and pharmaceutical companies — building the DCF, NPV, IRR and scenario models leadership uses to allocate capital.
Who is Long Range Advisory for?
Executive teams at emerging biotech and pharma companies: CFOs, VPs of Finance and CEOs facing a pipeline, licensing, manufacturing or commercial investment decision that needs a defensible valuation behind it.
What is the difference between adjusted and unadjusted NPV?
Unadjusted NPV assumes technical success. Adjusted NPV risk-weights every cash flow by the probability of success. In the worked example on this site the same pipeline is worth $5.54B unadjusted and $4.08B adjusted — a $1.46B risk discount.
How much does an engagement cost?
Fixed fee against a written scope, agreed before work starts, and sized to the decision. Initial consultations are complimentary and focused on understanding your objectives before recommending next steps.